Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit
Serina Therapeutics (NYSE American: SER) announced that their Chief Development Officer, Randall Moreadith, MD, PhD, will present at the 3rd Annual LNP Immunogenicity & Toxicity Summit in Boston. The presentation focuses on their proprietary POZ-lipid technology, which shows promising results in improving lipid nanoparticle (LNP) formulations.
Key findings demonstrate that POZ-lipid did not trigger IgM or IgG antibody responses after repeated administration in animal testing. This contrasts with conventional PEG-lipids, which produced strong antibody responses. The absence of immune response to POZ-lipid suggests potential for developing safer LNP formulations, particularly significant given that anti-PEG antibody responses have been linked to hypersensitivity reactions in mRNA-based vaccine recipients.
Serina Therapeutics (NYSE American: SER) ha annunciato che il loro Chief Development Officer, Randall Moreadith, MD, PhD, presenterà al 3° Summit Annuale sull'Immunogenicità e Tossicità dei LNP a Boston. La presentazione si concentra sulla loro tecnologia proprietaria POZ-lipid, che mostra risultati promettenti nel miglioramento delle formulazioni di nanoparticelle lipidiche (LNP).
I principali risultati dimostrano che il POZ-lipid non ha attivato risposte anticorpali IgM o IgG dopo somministrazione ripetuta nei test animali. Questo è in contrasto con i PEG-lipid convenzionali, che hanno prodotto forti risposte anticorpali. L'assenza di risposta immunitaria al POZ-lipid suggerisce un potenziale per sviluppare formulazioni LNP più sicure, particolarmente significativo dato che le risposte anticorpali anti-PEG sono state associate a reazioni di ipersensibilità nei destinatari di vaccini basati su mRNA.
Serina Therapeutics (NYSE American: SER) anunció que su Director de Desarrollo, Randall Moreadith, MD, PhD, presentará en la 3ª Cumbre Anual sobre Inmunogenicidad y Toxicidad de LNP en Boston. La presentación se centra en su tecnología propietaria POZ-lipid, que muestra resultados prometedores en la mejora de las formulaciones de nanopartículas lipídicas (LNP).
Los hallazgos clave demuestran que el POZ-lipid no desencadenó respuestas de anticuerpos IgM o IgG después de la administración repetida en pruebas en animales. Esto contrasta con los PEG-lípidos convencionales, que produjeron fuertes respuestas de anticuerpos. La ausencia de respuesta inmunitaria al POZ-lipid sugiere un potencial para desarrollar formulaciones de LNP más seguras, especialmente significativo dado que las respuestas de anticuerpos anti-PEG se han relacionado con reacciones de hipersensibilidad en los receptores de vacunas basadas en ARN mensajero.
Serina Therapeutics (NYSE American: SER)는 그들의 최고 개발 책임자인 Randall Moreadith, MD, PhD가 보스턴에서 열리는 제3회 연례 LNP 면역원성 및 독성 정상 회의에서 발표할 것이라고 발표했습니다. 이 발표는 그들의 독점 기술인 POZ-lipid 기술에 중점을 두고 있으며, 이는 지질 나노입자(LNP) 제형 개선에 대한 유망한 결과를 보여줍니다.
주요 발견은 POZ-lipid가 동물 실험에서 반복적인 투여 후 IgM 또는 IgG 항체 반응을 유도하지 않았다는 것입니다. 이는 강력한 항체 반응을 생성한 기존 PEG-지질과 대조적입니다. POZ-lipid에 대한 면역 반응이 없다는 것은 특히 mRNA 기반 백신 수신자에서 반응형 PEG 항체가 과민 반응과 연관되었다는 점에서 보다 안전한 LNP 제형 개발의 잠재력을 시사합니다.
Serina Therapeutics (NYSE American: SER) a annoncé que son directeur du développement, Randall Moreadith, MD, PhD, présentera au 3ème Sommet Annuel sur l'Immunogénicité et la Toxicité des LNP à Boston. La présentation se concentre sur leur technologie propriétaire POZ-lipid, qui montre des résultats prometteurs pour l'amélioration des formulations de nanoparticules lipidiques (LNP).
Les résultats clés montrent que le POZ-lipid n'a pas déclenché de réponses d'anticorps IgM ou IgG après une administration répétée lors d'essais sur des animaux. Cela contraste avec les PEG-lipides conventionnels, qui ont produit des réponses anticorporelles fortes. L'absence de réponse immunitaire au POZ-lipid suggère un potentiel pour le développement de formulations LNP plus sûres, ce qui est particulièrement significatif étant donné que les réponses des anticorps anti-PEG ont été liées à des réactions d'hypersensibilité chez les receveurs de vaccins à base d'ARNm.
Serina Therapeutics (NYSE American: SER) gab bekannt, dass ihr Chief Development Officer, Randall Moreadith, MD, PhD, auf dem 3. jährlichen LNP-Immunogenitäts- und Toxizitätssummit in Boston präsentieren wird. Die Präsentation konzentriert sich auf ihre proprietäre POZ-lipid-Technologie, die vielversprechende Ergebnisse bei der Verbesserung von Lipid-Nanopartikel (LNP)-Formulierungen zeigt.
Wichtige Ergebnisse zeigen, dass POZ-lipid nach wiederholter Verabreichung in Tierversuchen keine IgM- oder IgG-Antikörperreaktionen auslöste. Dies steht im Gegensatz zu konventionellen PEG-Lipiden, die starke Antikörperreaktionen hervorriefen. Das Fehlen einer Immunantwort auf POZ-lipid deutet auf ein Potenzial zur Entwicklung sichererer LNP-Formulierungen hin, was insbesondere bedeutsam ist, da Antikörperreaktionen gegen PEG mit Überempfindlichkeitsreaktionen bei Empfängern von mRNA-basierten Impfstoffen in Verbindung gebracht wurden.
- None.
- None.
HUNTSVILLE, AL, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, announced that Serina Therapeutics' Chief Development Officer, Randall Moreadith, MD, PhD, will be presenting today at the 3rd Annual LNP Immunogenicity & Toxicity Summit in Boston, MA. Entitled "Overcoming Anti-PEG Antibody Responses – A Novel PEOZ-lipid That Fails to Elicit an Immune Response to the Polymer-lipid in mRNA-LNP Formulations."
Dr. Moreadith will present data on the immunological profile of Serina's proprietary POZ-lipid, a next-generation polymer in development to improve lipid nanoparticle (LNP) formulations. The study demonstrated that POZ-lipid did not induce IgM or IgG antibody responses following repeated administration in an animal model. In contrast, standard PEG-lipids commonly utilized in current LNP technologies elicited robust and sustained IgM and IgG responses. Such anti-PEG antibody responses have been implicated in hypersensitivity reactions, including anaphylaxis and other serious adverse events, in recipients of mRNA-based vaccines (e.g., Pfizer-BioNTech and Moderna). The absence of an IgM or IgG response to Serina's POZ-lipid is a notable observation that suggests its potential to enable the development of safer and more immunologically compatible LNP formulations.
About Serina Therapeutics
Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ Platform™ provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.
For more information, please visit https://serinatherapeutics.com.
Cautionary Statement Regarding Forward-Looking Statement
This release contains forward-looking statements within the meaning of federal securities laws. These statements are based on management’s current expectations, plans, beliefs or forecasts for the future, and are subject to uncertainty and changes in circumstances. Any express or implied statements in this press release that are not statements of historical fact, including statements about the potential of Serina’s POZ polymer technology, are forward-looking statements that involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when any applications may be filed for any drug or vaccine candidates in any jurisdictions; whether and when regulatory authorities may approve any potential applications that may be filed for any drug or vaccine candidates in any jurisdictions, which will depend on a myriad of factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether any such drug or vaccine candidates will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of any drug or vaccine candidates; and competitive developments. These risks as well as other risks are more fully discussed in the company’s Annual Report on Form 10-K for the year ended December 31, 2023, the company’s Current Report on Form 8-K that was filed with the SEC on April 1, 2024, and the company’s other periodic reports and documents filed from time to time with the SEC.
The information contained in this release is as of the date hereof, and Serina assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
For inquiries, please contact:
Stefan Riley
sriley@serinatherapeutics.com
(256) 327-9630
FAQ
What breakthrough did Serina Therapeutics (SER) announce about their POZ-lipid technology in December 2024?
How does Serina's (SER) POZ-lipid differ from current PEG-lipids used in mRNA vaccines?
What are the safety implications of Serina's (SER) POZ Platform technology for mRNA vaccines?
Where did Serina Therapeutics (SER) present their POZ-lipid research findings in December 2024?
